Anonymous
Not logged in
Talk
Contributions
Create account
Log in
Search
Editing
Journal of Chronic Fatigue Syndrome: Volume 1, Issue 1, 1995
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
Namespaces
Page
Discussion
More
More
Page actions
Read
Edit
Edit source
History
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
Titles and abstracts for the [[Journal of Chronic Fatigue Syndrome]], Volume 1, Issue 1, 1995. ==Volume 1, Issue 1, 1995== *''The Birth of a Journal'' by [[Nancy Klimas]] & [[Roberto Patarca-Montero | Roberto Patarca]]<ref name="Klimas, Patarca, 1995" /> *Guest Editorial - ''Psychoneuroimmunology and [[Chronic Fatigue Syndrome]]: Toward New Models of Disease''<ref name="Solomon, 1995" /> *Review - ''[[Chronic Fatigue Syndrome]] in Children''<blockquote> "Abstract - [[Chronic fatigue syndrome]] ([[chronic fatigue syndrome|CFS]]), formerly called chronic [[Epstein-Barr virus]] syndrome, chronic [[mononucleosis]], and numerous other names, is a symptom complex characterized by marked functional limitation which affects children as well as adults. The symptom complex, physical examination, laboratory evaluation, clinical course, and differential diagnosis are reviewed with particular emphasis upon CFS in children. Management consists of a comprehensive treatment plan including medical, educational, and psychosocial support wiih the aim of reducing both symptom and activity limitation. While etiology is unknown, the use of the term "chronic fatigue syndrome" is appropriate for children with marked functional limitation due to unexplained fatigue who have the associated symptom complex and physical examination findings characteristic of this condition."<ref>{{Cite journal | last1 = Bell | first1 = David S. | authorlink = David Bell | title = Chronic Fatigue Syndrome in Children|journal=Journal of Chronic Fatigue Syndrome|volume=1|issue=1 | page = 9-33 | date = 1995|pmid= |doi=10.1300/J092v01n01_03}}</ref></blockquote> *''Long Term Improvements in Patients with [[Chronic Fatigue Syndrome]] Treated with [[Ampligen]]''<blockquote>"Abstract- Fifteen patients who fit the [[Centers for Disease Control and Prevention|CDC]] definition of [[chronic fatigue syndrome]] (CFS) and had evidence of severe reduction in performance levels by low [[Karnofsky Performance Scale|Karnofsky performance score]]s (KPS) of 20-60 were treated with [[Ampligen]]. At baseline most patients showed evidence of cerebral dysfunction by neuropsychological testing, were antigen positive by cell culture assay for human herpesvirus-6 (HHV-6), and displayed reduced performance during exercise tolerance testing, as measured by oxygen consumption. These patients represented a subset of [[chronic fatigue syndrome|CFS]] patients with especially severe and sustained symptomatology. Following 1248 weeks of [[Ampligen]] therapy, sustained improvements were noted in KPS (p < 0.01). Cognitive function improved including IQ and memory. Oxygen uptake and treadmill duration during exercise tolerance testing was also improved after 24 weeks of treatment (p < 0.01). Reduction in [[Human herpesvirus 6]] expression as measured by the giant cell assay was significant (p < 0.001). Patients continued to show significant improvement late in therapy, taking 8 to 12 weeks as baseline. It was concluded that while receiving [[Ampligen]], the severely afflicted patients studied here derived long-lasting clinical benefit from the [[Ampligen]] therapy."<ref name="Strayer,1995" /></blockquote> *''The Assessment of Vascular Abnormalities in Late Life [[Chronic Fatigue Syndrome]] by Brain [[SPECT]]: Comparison with Late Life Major Depressive Disorder''<blockquote>"Abstract- We report on brain [[SPECT]] analysis of regional cerebral blood flow (rCBF) in late life chronic fatigue syndrome (CFS) patients and compare their results with patients with late life depression and elderly normal controls 45 years and older. We attempted to distinguish CFS from normals and patients with depression and applied the findings to understand the pathophysiology of the illness. We studied 33 patients with CFS (55 ± 10 years), 26 patients with late life depression (62 ± 8 years), and 19 normal controls (66 ± 8 years); 43 other normal controls had only ¹³³Xe rCBF measurements (66 ± 8 years). We evaluated rCBF quantitatively with ¹³³Xe images and qualitatively with high resolution imaging using 99mTc-HMPAO. We found that rCBF in CFS measured by ¹³³Xe varied between 35 and 41 ml/min/l00g in both hemispheres, p < 0.0001 and 0.05; similar findings were observed in depression. In CFS 99mTc-HMPAO imagain demonstrated right orbitofrontal and marked right dorsofrontal hypoperfusion at 58% to 66% of the maximal activity in the brain, p , 0.001. In late life depression, hypoperfusion was primarily limited to the right orbitofrontal lobe, 42% and 57%, p , 0.001. In depression, the abnormalities were most striking in the left temporal lobe and particularly in the left anterior frontal lobes. CFS patients with major depressive disorder by DMS-III-R criteria did not differ in regional [[cerebral hypoperfusion]] from those without major depression. The pathophysiology of the illness may involve the dysregulation of a neural network which includes circuits between the hippocampus (located in the anterior temporal lobe) and the dorsolateral prefrontal cortex."<ref name="Goldstein, 1995" /></blockquote> *''Dysregulated Expression of Soluble Immune Mediator Receptors in a Subset of Patients with Chronic Fatigue Syndrome: Cross-Sectional Categorization of Patients by Immune Status<blockquote>"Abstract-Individuals with chronic fatigue syndrome (CFS) have significantly increased proportions of activated CD8+T cells, decreased natural killer (NK) cell cytotoxic and lymphoproliferative activities, elevated serum levels of tumor necrosis factor (TNF)-α and detectable TNF-β, interleukin (IL)-lβ, and IL-6 mRNA in peripheral blood mononuclear cells (PBMC). We report here that CFS patients as a group also have significantly higher levels, as compared to controls, of soluble TNF receptor type I (sTNF-RI or sCDl20a), sIL-6R (sCD126) and β2-microglobulin (β2-m), but not of IL-1 receptor antagonist (IL-1Ra). Correlative and population distribution studies that included lymphoid phenotypic distributions and function as well as soluble immune mediator expression levels revealed the existence of at least two mainly nonoverlapping immunological categories among CFS patients with either: (1) dysregulaled TNF-α/β expression in association with changes in the serum levels of IL-lα, IL-4, sIL-2R and IL-lRa, PBMC-associated expression of IL-1β, IL-6 and TNF-β mRNA, and T cell activation; or, (2) interrelated and dysregulated expression of sTNF-RI, sIL-6R, and β2-m and significantly decreased lymphoproliferative and NK cell cytotoxic activities. This preliminary systematization is of usefulness in the diagnosis, follow-up, and characterization of possible etiological agents for CFS."<ref name="Patarca, 1995" /></blockquote>'' *''National Institutes of Health Workshop Statement NIH Technology Assessment Workshop on the Persian Gulf Experience and Health April 27-29,1994''<ref name="NIHWorkshop, 1995" /> *''Literature In Review''<ref name="LitReview, 1995" /> ==See also== *[[Journal of Chronic Fatigue Syndrome]] for other Issues ==References== <references> <ref name="Goldstein, 1995">{{Citation | last = Goldstein | first1 = Jay A. | authorlink1 = Jay Goldstein | last2 = Mena | first2 = Ismael | authorlink2 = Ismael Mena | last3 = Jouanne | first3 = Eugenio | authorlink3 = | last4 = Lesser | first4 = Ira | authorlink4 = | title = The Assessment of Vascular Abnormalities in Late Life Chronic Fatigue Syndrome by Brain SPECT: Comparison with Late Life Major Depressive Disorder | journal = Journal of Chronic Fatigue Syndrome | volume = 1 | issue = 1 | page = 55-79 | date = 1995 | pmid = | doi = 10.1300/J092v01n01_05 | url=|pages=|chapter=|edition=|isbn=}}</ref> <ref name="NIHWorkshop, 1995">{{Citation | last = Haworth Continuing Features Submission | first1 = | authorlink1 = | title = National Institutes of Health Workshop Statement NIH Technology Assessment Workshop on the Persian Gulf Experience and Health April 27-29,1994 | journal = Journal of Chronic Fatigue Syndrome | volume = 1 | issue = 1 | page = 97-112 | date = 1995 | pmid = | doi = 10.1300/J092v01n01_07 }}</ref> <ref name="Klimas, Patarca, 1995">{{Citation | last = Klimas | first1 = Nancy | authorlink1 = Nancy Klimas | last2 = Patarca | first2 = Roberto | authorlink2 = Roberto Patarca-Montero | title = The Birth of a Journal | journal = Journal of Chronic Fatigue Syndrome | volume = 1 | issue = 1 | page = 1-2 | date = 1995 | pmid = | doi = 10.1300/J092v01n01_01 }}</ref> <ref name="LitReview, 1995">{{Citation | last = Haworth Continuing Features Submission | first1 = | authorlink1 = | title = LITERATURE IN REVIEW | journal = Journal of Chronic Fatigue Syndrome | volume = 1 | issue = 1 | page = 113-125 | date = 1995 | pmid = | doi = 10.1300/J092v01n01_08 }}</ref> <ref name="Patarca, 1995">{{Citation | last = Patarca | first1 = Patarca | authorlink1 = Roberto Patarca-Montero | last2 = Klimas | first2 = Nancy | authorlink2 = Nancy Klimas | last3 = Garcia | first3 = Maria N. | authorlink3 = | last4 = Walters | first4 = Michael J. | authorlink4 = | last5 = Dombroski | first5 = Derek | authorlink5 = | last6 = Pons | first6 = Hector| authorlink6 = | last7 = Fletcher | first7 = Mary Ann | authorlink7 = Mary Ann Fletcher | title = Dysregulated Expression of Soluble Immune Mediator Receptors in a Subset of Patients with Chronic Fatigue Syndrome: Cross-Sectional Categorization of Patients by Immune Status | journal = Journal of Chronic Fatigue Syndrome | volume = 1 | issue = 1 | page = 81-96 | date = 1995 | pmid = | doi = 10.1300/J092v01n01_06 }}</ref> <ref name="Solomon, 1995">{{Citation | last = Solomon | first1 = George Freeman | authorlink1 = | title = Psychoneuroimmunology and Chronic Fatigue Syndrome: Toward New Models of Disease | journal = Journal of Chronic Fatigue Syndrome | volume = 1 | issue = 1 | page = 3-7 | date = 1995 | pmid = | doi = 10.1300/J092v01n01_02 }}</ref> <ref name="Strayer,1995">{{Citation | last = Strayer | first1 = DR | authorlink1 = David Strayer | last2 = Carter | first2 = W | authorlink2 = William Carter | last3 = Strauss | first3 = KI | authorlink3 = Kenneth Strauss | last4 = Brodsky | first4 = I | authorlink4 = | last5 = Suhadolnik | first5 = R | authorlink5 =Robert Suhadolnik | last6 =Ablashi | first6 = D | authorlink6 = Dharam Ablashi | last7 = Henry | first7 = B | authorlink7 = | last8 =Mitchell | first8 = WM | authorlink8 = William Mitchell | last9 = Bastien | first9 = S | authorlink9 =Sheila Bastien | last10 = Peterson | first10 = D | authorlink10 = Daniel Peterson | title = Long Term Improvements in Patients with Chronic Fatigue Syndrome Treated with Ampligen | journal = Journal of Chronic Fatigue Syndrome | volume = 1 | issue = 1 | page = 35-53 | date = 1995 | doi = 10.1300/J092v01n01_04 | url=|pages=|chapter=|edition=|isbn=}}</ref> </references> [[Category:Journal issues]] [[Category:Journal of Chronic Fatigue Syndrome issues]]
Summary:
Please make sure your edits are consistent with
MEpedia's guidelines
.
By saving changes, you agree to the
Terms of use
, and you irrevocably agree to release your contribution under the
CC BY-SA 3.0 License
and the
GFDL
. You agree that a hyperlink or URL is sufficient attribution under the Creative Commons license.
Cancel
Editing help
(opens in new window)
Templates used on this page:
Template:Citation
(
edit
)
Template:Cite journal
(
edit
)
Module:Citation/CS1
(
edit
)
Module:Citation/CS1/COinS
(
edit
)
Module:Citation/CS1/Configuration
(
edit
)
Module:Citation/CS1/Date validation
(
edit
)
Module:Citation/CS1/Identifiers
(
edit
)
Module:Citation/CS1/Utilities
(
edit
)
Module:Citation/CS1/Whitelist
(
edit
)
Module:No globals
(
edit
)
Navigation
Navigation
Skip to content
Main page
Browse
Become an editor
Random page
Popular pages
Abbreviations
Glossary
About MEpedia
Links for editors
Contents
Guidelines
Recent changes
Pages in need
Search
Help
Wiki tools
Wiki tools
Special pages
Page tools
Page tools
User page tools
More
What links here
Related changes
Page information
Page logs